GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jacobson Pharma Corp Ltd (HKSE:02633) » Definitions » Net Change in Cash

Jacobson Pharma (HKSE:02633) Net Change in Cash : HK$-355 Mil (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jacobson Pharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Jacobson Pharma's Net Change in Cash for the six months ended in Sep. 2024 was HK$104 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was HK$-355 Mil.

Jacobson Pharma Net Change in Cash Historical Data

The historical data trend for Jacobson Pharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobson Pharma Net Change in Cash Chart

Jacobson Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -208.40 58.91 -1.70 457.77 -524.48

Jacobson Pharma Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 381.76 76.01 -65.37 -459.11 103.97

Jacobson Pharma Net Change in Cash Calculation

Jacobson Pharma's Net Change in Cash for the fiscal year that ended in Mar. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=484.363+43.342+-1053.255+1.069
=-524

Jacobson Pharma's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=277.366+-80.396+-91.78+-1.225
=104

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-355 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobson Pharma Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Jacobson Pharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Jacobson Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jacobson Pharma Corp Ltd (HKSE:02633) » Definitions » Net Change in Cash
Comparable Companies
HKSE:01061 HKSE:02552 HKSE:02161 HKSE:02348 HKSE:06896 HKSE:08049 HKSE:00950 HKSE:03737 HKSE:00239 HKSE:08329 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
388 Kwun Tong Road, Unit 2313-18, 23rd Floor, Tower 1, Millennium City 1, Kwun Tong, Kowloon, Hong Kong, HKG
Website
http://www.jacobsonpharma.com
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
Executives
Queenshill Development Limited
Sum Kwong Yip, Derek 2305 Beneficiary of a trust
Lau Wing Hung
Kingshill Development Group Inc
Kingshill Development Limited
Ubs Trustees (b.v.i.) Limited
Longjin Investments Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si

Jacobson Pharma Headlines

No Headlines